pharma

Lupin

LUPIN · Nifty 50

2,272

Price 2026-06-17

BROAD EXPANSION73% confidence

At a Glance

Sector Positionpharma sector. Flow: neutral. is not among current leaders. Regime: BROAD EXPANSION (73%).
Fundamental Score100/100 (STRONG). 0 positive flags, 4 concerns.
Historical Context13 similar technical setups. Average outcome: -7.1% decline. 0% positive.

Fundamental

100/100

STRONG

Trust

95/100

Verification

Coverage

44/100

LIMITED

Quick Take

Lupin scores 100/100 on fundamentals (strong). Lupin: BROAD EXPANSION regime.

Fundamental Score: 100/100 · STRONG · 1 signals detected

DuPont Analysis

ROE 20.6% broken into three drivers. Each shows how efficiently the company generates returns.

ROE20.6%=
17.6%Net Margin
×
0.7xTurnover
×
1.7xLeverage

ROE of 20.61% is strong margin-driven and stable. Net margin of 17.6% × asset turnover of 0.68x × leverage of 1.7x.

What This Means

Net margin of 17.6% means the company keeps ₹17.6 as profit for every ₹100 of revenue. This is a healthy margin. Asset turnover of 0.68x means the company efficiently uses its assets to generate revenue. Leverage of 1.7x means the company uses moderate debt. Returns are primarily driven by operations, not borrowing.

Margin Structure

Gross

72.6%

Operating

23.6%

Net

17.6%

improving

Gross margin 72.6% → operating margin 23.6% → net margin 17.6%. Margins are IMPROVING. Strong pricing power with stable gross margins suggests the improvement is from operating leverage — sustainable.

Financial Health

Earnings Quality

STRONG

Cash flow covers net income 1.6x — earnings are HIGH QUALITY. The company converts profit to cash efficiently.

Debt Sustainability

COMFORTABLE

Interest covered 14.8x — very comfortable. Debt service is not a concern. Debt/EBITDA at 0.9x is low — balance sheet has capacity.

Free Cash Flow

STRONG

FCF margin at 20.1% — strong cash generation. Business is self-funding.

Peer Comparison

Lupin is compared against 10 peers in the pharma sector.

Key Watchpoints

🟢

Breaks above ₹2386 (+5%)

Trend reversal confirmation

🔴

Breaks below ₹2158 (-5%)

Further downside risk

🟢

Pharma sector entering leadership

Sector rotation signal

Detected Patterns

✅ High Earnings Quality: Cash flow covers earnings 1.6x — strong cash conversion

Risk Flags

🔴 1 Critical⚠️ 3 Warning4 total flags
🔴Unusual items are 63% of net income
Earnings Quality

One-off items significantly inflating reported profit. Core earnings may be much lower.

⚠️Special charges present in income statement
Earnings Quality

Special charges of ₹2941K Cr. May indicate restructuring, impairment, or one-time costs.

⚠️64% of debt is short-term
Balance Sheet

High refinancing risk. Company needs to roll over debt frequently. Vulnerable to credit market freezes.

⚠️Cash covers 33% of current liabilities
Balance Sheet

Tight liquidity. Monitor cash position and access to credit lines.

⚠️ 1 critical + 3 warning flags. Exercise caution.

Data Quality

95/100All ratios self-computed from verified sources. 🟢 5 years of financial data — sufficient for trend analysis

News Correlation

margin pressure (4)management outlook (4)
⚠️ Our margin analysis (improving) contradicts news reports of margin pressure — investigate

50 articles scanned for fundamental themes

Facts

P/E Ratio
19.7UNAVAILABLE
P/B Ratio
4.7HIGH
Market Cap
₹10485714.1L CrHIGH
From 52W High
91% of high
Sector Peers
10
Lupin Stock Analysis, Valuation, Fundamentals & Intelligence | FynSight